Loading company…
NeuroThree Therapeutics develops central nervous system drug candidates, including treatments for epilepsy.
Founded in 2022 and based in Suzhou, China, NeuroThree Therapeutics develops drugs for neuroexcitability and neurodegenerative diseases. Its pipeline includes clinical-stage small molecules for epilepsy, Parkinson's disease, and pain, as well as preclinical siRNA research. Founder Li Zheng has more than 20 years of CNS development experience and previously served as senior vice president of R&D at Pfizer and GSK China. In March 2025, it closed a pre-Series A funding round with new investor Jiangsu Nhwa Pharmaceutical Co., Ltd.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in